tbuckley/cabot-search huggingface dataset:
GABA<sub>B</sub>receptor modulation of visual sensory processing in adults with and without autism spectrum disorder
Authors: Qiyun Huang, Andreia C. Pereira, Hester Velthuis, Nichol M. L. Wong, Claire L. Ellis, Francesca M. Ponteduro, Mihail Dimitrov, Lukasz Kowalewski, David J. Lythgoe, Diana Rotaru, Richard A. E. Edden, Alison Leonard, Glynis Ivin, Jumana Ahmad, Charlotte M. Pretzsch, Eileen Daly, Declan G. M. Murphy, Gráinne M. McAlonan
Journal: Science Translational Medicine (2022)

Differences in GABAergic function are critical to autistic visual sensory neurobiology and can be modulated by targeting GABA B .
From the Health Resources and Services Administration
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P362: Significant Positive Association Between Alcohol Consumption and Advanced Aortic Calcification in an International Multiethnic Cohort of 1335 Men Aged 40-49 Years: The ERA JUMP Study
Authors: Hemant Mahajan, Jingchuon Guo, Siyi Shangguan, Bradley Willcox, Katsuyuki Miura, Tonomori Okamura, Akira Fujiyoshi, Jina Choo, Rhobert Evans, Emma Barinas-Mitchell, Lewis Kuller, Chol Shin, Kamal Masaki, Hirotusugu Ueshima, Akira Sekikawa
Journal: Circulation (2017)

Introduction: Aortic calcification (AC) is a less widely used measure of atherosclerosis, has been linked to cardiovascular (CV) morbidity and mortality. A J-shaped association of alcohol consumption with CHD has been consistently reported in epidemiological studies. However, scanty literature is available describing the association of alcohol consumption and AC. Hypothesis: We hypothesized that alcohol consumption has a J-shaped association with advanced AC. Method: ERA JUMP is a population-based study of subclinical atherosclerosis in 1335 men aged 40-49 years without CVD (310 European American, 107 African American, 303 Japanese American, 313 Japanese in Japan and 308 Korean in South Korea). Participants were examined for AC, alcohol consumption, CV risk and other factors in 2002-07 with rigorous standardization. AC was assessed by electron-beam CT and quantified using the Agatston method. Advanced AC was defined as Agatston calcium score ≥300. Alcohol consumption was categorized into four groups: 0 (non-drinkers), &lt;1 (light drinkers), &gt; 1 to &lt; 3 (moderate drinkers) and &gt;3 drinks per day (heavy drinkers) (1 drink=12.5 grams of ethanol). Multivariable logistic regression was used to assess the relationship between AC with alcohol consumption adjusting for age, race, CV risk and other factors. Results: Among 1299 studied participants, after excluding participants with missing values for AC (n=36), 70.3% (913 of 1299) were current drinkers and 10.9% (142 of 1299) had advanced AC. Prevalence of advanced AC among non, light, moderate, and heavy drinkers was 7.25% (28 of 386), 10.89% (43 of 395), 9.06% (28 of 309), and 20.57% (43 of 209) respectively. Alcohol consumption had a positive association with advanced AC with a significant cubic trend (p&lt;0.01). There was no significant interaction on advanced AC between race and alcohol consumption. Conclusion: A significant positive association between alcohol consumption and advanced AC was observed in this cross-sectional study of an international multi-ethnic cohort.
Phase II trial of moderate dose omega-3 acid ethyl esters for colorectal cancer prevention in patients with lynch syndrome (COLYNE).
Authors: Khalil Choucair, Dan Dixon, Ajay Bansal, Jennifer R. Klemp, Yazan Abdulateef, Prabhakar Chalise, Raed Moh'd Taiseer Al-Rajabi, Anup Kasi, Stephen K. Williamson, Joaquina Celebre Baranda, Weijing Sun, Anwaar Saeed
Journal: Journal of Clinical Oncology (2022)

TPS209 Background: Lynch syndrome (LS) is the most common inherited colorectal cancer (CRC) syndrome and is responsible for about 3% of newly diagnosed CRC. It is caused by germline mutations in one of the DNA mismatch repair (MMR) genes, and patients with LS carry a lifetime risk of CRC ranging between 10% and 70%. The role of inflammation in driving this malignant transformation is now well established and retrospective studies have revealed a potential chemo-preventative role for omega-3 (ω-3) polyunsaturated fatty acids (PUFAs), possibly via inhibition of inflammatory pathways associated with the development of defective MMR CRC tumors. While patients with LS have the highest risk of developing CRC, the majority of chemoprevention trials are focused on sporadic CRC. Effective interventions to reduce the risk of developing CRC in this population are limited to close surveillance and surgical prophylaxis. There is an unmet need for safe, effective, and non-invasive chemo-preventive interventions in patients with LS. Methods: This pilot study is a single-arm, open-label, phase 2 clinical trial of omega-3 acid ethyl esters (generic Lovasa; 2 grams orally once daily) for adult patients (≥ 18 years of age) with confirmed LS (based on germline testing of the MMR genes panel: MLH1, MSH2, MSHS6, PMS2 or deletion in EPCAM gene). Patients who are not candidate for elective endoscopy and/or with prior history of right sided or pan-colectomy are excluded. Thirty-four patients are expected to enroll, with a primary objective to determine the feasibility (defined as 80% retention rate) of 12 months of treatment with 2 grams capsules of omega-3 acid ethyl esters daily. Secondary endpoints include safety and tolerability of the intervention. Correlative aims include pre and post treatment assessment of colon mucosal tissue proliferation (right sided colon specimens will be evaluated for markers of proliferation (Ki-67) and apoptosis (Caspase-3)), the effect of omega-3 acid ethyl esters on inflammatory markers in serum, urine and feces (PGE-2, COX-2, β-catenin levels, and EPA:AA ratios), and gene expression related to proliferation, apoptosis and cell survival in colon tissue (NF-κB/Wnt pathways). The impact of omega-3 acid ethyl esters on intestinal microbiota will also be assessed (16S rRNA-based profiling). Correlative Colon tissue, serum, urine and feces samples are collected at baseline and at 12 months. The study is actively enrolling with 20 patients enrolled at the time of submission. Clinical trial information: NCT03831698.
Left ventricular-mechanical mapping in patients without previous myocardial infarction: Comparison with stress perfusion imaging Irene Bossi, Glen Van Langenhvoe, Jean Fajadet, Patrick Serruys, Nicolas Fourquet, Catherine Klersy, Jean Marco. Clinique Pasteur, Toulouse, Thorax Center, Rotterdam, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Clinical Science
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Books Received.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.
Authors: Karyn A. Goodman, Rui-hua Xu, Ian Chau, Ming Huang Chen, Byoung Chul Cho, Manish A. Shah, Kei Muro, Yifan Wang, Mari Ichimaru, Qingyuan Liu, Luhua Wang
Journal: Journal of Clinical Oncology (2022)

TPS374 Background: The current standard of care for patients (pts) diagnosed with unresectable, locally advanced esophageal squamous-cell carcinoma (ESCC) is definitive platinum-based concurrent chemoradiotherapy (dCRT). However, ESCC has poor prognosis, with more than half of tumors reoccurring after dCRT (Smyth et al. Nat Rev Dis Primers 2017), highlighting the need for additional therapy options in this setting. Cancer immunotherapies have demonstrated activity in ESCC, and targeted inhibition of the PD-L1/PD-1 pathway may be further amplified using novel anti-TIGIT agents such as tiragolumab. In preclinical mouse models, concomitant blockade of PD-L1/PD-1 and TIGIT pathways demonstrated prolonged survival over the respective single-agents. In the phase II CITYSCAPE study (NCT03563716), tiragolumab plus atezolizumab (anti-PD-L1) resulted in a clinically meaningful improvement in PFS and higher ORR vs atezolizumab alone (31.3 vs 16.2%) in first-line pts with PD-L1+ (TPS ≥1%) metastatic NSCLC. SKYSCRAPER-07 (NCT04543617) will determine if tiragolumab plus atezolizumab combination therapy provides superior clinical benefit to atezolizumab monotherapy or placebo in pts with unresectable ESCC whose cancers have not progressed following dCRT. We hypothesize that combination therapy will prolong PFS and OS compared with placebo in this setting. Methods: Eligible pts (≥18 years) must have unresectable ESCC, without progressive disease (PD) after platinum-based dCRT (according to regional oncology guidelines for ESCC); ECOG PS 0–1; no prior treatment with any immune checkpoint inhibitor. Approximately 750 pts will be randomized 1:1:1 to either Arm A (tiragolumab 600mg + atezolizumab 1200mg IV Q3W), Arm B (atezolizumab 1200mg + placebo IV Q3W) or Arm C (double placebo IV Q3W). Treatment will continue for up to 17 cycles of 21 days, or until unacceptable toxicity or investigator-assessed radiographic PD (per RECIST v1.1). Stratification factors include geographic region (Asia vs rest of world), PD-L1 expression and staging prior to dCRT (II vs III vs IV). Co-primary efficacy endpoints are investigator-assessed PFS and OS; key secondary endpoints include independent review facility-assessed PFS and DoR. Safety, pharmacokinetic, biomarker and immunogenicity analyses will be performed. Recruitment is ongoing. Clinical trial information: NCT04543617.
Personalized and Programmable Microneedle Dressing for Promoting Wound Healing (Adv. Healthcare Mater. 2/2022)
Authors: Yuqiu Wang, Huihui Lu, Maoze Guo, Jianlin Chu, Bingbing Gao, Bingfang He
Journal: Advanced Healthcare Materials (2022)

Programmable Needles In article number 2101659 by Jianlin Chu, Bingbing Gao, and co-workers, a mosquito mouthpart structure-inspired microneedle dressing with personalized patterns, programmable needle length, multiple mechanical strength, superfine needle tips, and intelligent drug release is fabricated by replicating stretched negative molds. The two different materials, silk fibroin (SF) and polyurethane (PU), endow the microneedle (MN) dressing with better fixed effect and painless drug release. The MN dressing also present an outstanding applicability of promoting wound healing.
CHLOROTHIAZIDE DERIVATIVES FOR DIABETES INSIPIDUS
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review La Technique de la Curiethérapie (The Technique of Radium Therapy) . By Le Dr. Simone Laborde, Chief of Service of Radium Therapy at the Institute of Cancer. Published by Gauthier-Villars et Cie, Editeurs. Paris, 1933. Paper. 118 pages. Price 20 francs.
Journal: New England Journal of Medicine (1933)
Gait instability and estimated core temperature predict exertional heat stroke
Authors: Mark Buller, Rebecca Fellin, Max Bursey, Meghan Galer, Emma Atkinson, Beth A Beidleman, Michael J Marcello, Kyla Driver, Timothy Mesite, Joseph Seay, Lara Weed, Brian Telfer, Christopher King, Royce Frazee, Charles Moore, James R Williamson
Journal: British Journal of Sports Medicine (2022)

Exertional heat stroke (EHS), characterised by a high core body temperature (Tcr) and central nervous system (CNS) dysfunction, is a concern for athletes, workers and military personnel who must train and perform in hot environments. The objective of this study was to determine whether algorithms that estimate Tcr from heart rate and gait instability from a trunk-worn sensor system can forward predict EHS onset.Heart rate and three-axis accelerometry data were collected from chest-worn sensors from 1806 US military personnel participating in timed 4/5-mile runs, and loaded marches of 7 and 12 miles; in total, 3422 high EHS-risk training datasets were available for analysis. Six soldiers were diagnosed with heat stroke and all had rectal temperatures of >41°C when first measured and were exhibiting CNS dysfunction. Estimated core temperature (ECTemp) was computed from sequential measures of heart rate. Gait instability was computed from three-axis accelerometry using features of pattern dispersion and autocorrelation.The six soldiers who experienced heat stroke were among the hottest compared with the other soldiers in the respective training events with ECTemps ranging from 39.2°C to 40.8°C. Combining ECTemp and gait instability measures successfully identified all six EHS casualties at least 3.5 min in advance of collapse while falsely identifying 6.1% (209 total false positives) examples where exertional heat illness symptoms were neither observed nor reported. No false-negative cases were noted.The combination of two algorithms that estimate Tcr and ataxic gate appears promising for real-time alerting of impending EHS.
Surgical management of Curling's ulcer in children
Authors: A. Shaw
Journal: JAMA (1966)

SURGICAL correction of complications arising from Curling's ulcer in children has rarely been reported. We have been able to find only six acceptable reports of surgery in such cases. The earliest was Regenbrecht's<sup>1</sup>description in 1959 of closure of a perforated gastric ulcer 18 days following extensive body burns. The child died of bronchopneumonia on the 18th postoperative day. In 1960, Lasserre et al<sup>2</sup>reported a case of a 6 1/2-year-old girl who underwent partial duodenal resection and gastrojejunostomy for a bleeding Curling's ulcer located in the duodenum. The child lived and is believed to be the first survival documented in the literature. The second survival was reported by Leix and Greaney in 1963.<sup>3</sup>Their patient was a 2-year-old girl who underwent surgery for hemorrhage and perforation. The third survival was presented by Abramson<sup>4</sup>in 1964. He described a 10-year-old boy with extensive burns who underwent
Association between polymorphisms in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis Julian P. J. Halcox, David H. McDermott, Maya N. Merrell, Neal Epstein, Philip M. Murphy, Arshed A. Quyyumi. NIH, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)
Medical History
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Art and the Hospital
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Raloxifene effects on serum triglycerides in osteoporotic postmenopausal women: Influence of baseline triglyceride concentration and subject demographics Kristine D. Harper, Deborah Grady, Somnath Sarkar, David A. Cox, Elizabeth Barrett-Connor. Lilly Research Laboratories, Indianapolis, IN, UCSF, San Francisco, CA
Journal: Journal of the American College of Cardiology (2001)